Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer

详细信息    查看全文

• 作者：Gillian M. Keating
• 刊名：Drugs
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：76
• 期：9
• 页码：969-978
• 全文大小：544 KB
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1950
• 卷排序：76

文摘

The programmed death (PD)-1 immune checkpoint inhibitor nivolumab (Opdivo®) is approved in the USA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progression on or after platinum-based chemotherapy and in the EU for the treatment of adults with locally advanced or metastatic NSCLC after prior chemotherapy. In previously-treated patients with advanced nonsquamous NSCLC, overall survival was significantly prolonged and the overall response rate was significantly higher in patients who received intravenous nivolumab 3 mg/kg every 2 weeks versus intravenous docetaxel in the pivotal CheckMate 057 trial. Progression-free survival did not significantly differ between patients receiving nivolumab and those receiving docetaxel. Intravenous nivolumab had a manageable adverse event profile (including immune-mediated adverse events) and was better tolerated than docetaxel in the CheckMate 057 trial. Thus, nivolumab is an important new option for use in previously-treated patients with advanced nonsquamous NSCLC.The manuscript was reviewed by: E. Bria, Medical Oncology, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; J. R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA; R. A. Soo, Department of Haematology-Oncology, National University Cancer Institute and Cancer Science Institute of Singapore, National University of Singapore, Singapore.